437 related articles for article (PubMed ID: 23107595)
1. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of childhood rotavirus vaccination in Germany.
Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of rotavirus vaccination programs in Taiwan.
Chang WC; Yen C; Chi CL; Wu FT; Huang YC; Lin JS; Huang FC; Tate JE; Wu HS; Hsiung CA
Vaccine; 2013 Nov; 31(46):5458-65. PubMed ID: 24060569
[TBL] [Abstract][Full Text] [Related]
4. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
Abbott C; Tiede B; Armah G; Mahmoud A
Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
[TBL] [Abstract][Full Text] [Related]
8. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China.
Liu N; Yen C; Fang ZY; Tate JE; Jiang B; Parashar UD; Zeng G; Duan ZJ
Vaccine; 2012 Nov; 30(48):6940-5. PubMed ID: 22705174
[TBL] [Abstract][Full Text] [Related]
9. An economic analysis of rotavirus vaccination in Italy.
Giammanco MD; Coniglio MA; Pignato S; Giammanco G
Vaccine; 2009 Jun; 27(29):3904-11. PubMed ID: 19446934
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
[TBL] [Abstract][Full Text] [Related]
11. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq.
Weycker D; Sofrygin O; Kemner JE; Pelton SI; Oster G
Vaccine; 2009 Aug; 27(36):4930-7. PubMed ID: 19555715
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
14. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France.
Huet F; Largeron N; Trichard M; Miadi-Fargier H; Jasso-Mosqueda G
Vaccine; 2007 Aug; 25(34):6348-58. PubMed ID: 17629598
[TBL] [Abstract][Full Text] [Related]
15. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
[TBL] [Abstract][Full Text] [Related]
16. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
Atkins KE; Shim E; Carroll S; Quilici S; Galvani AP
Vaccine; 2012 Nov; 30(48):6766-76. PubMed ID: 23000223
[TBL] [Abstract][Full Text] [Related]
18. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
19. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
[TBL] [Abstract][Full Text] [Related]
20. Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model.
Bakir M; Standaert B; Turel O; Bilge ZE; Postma M
Vaccine; 2013 Jan; 31(6):979-86. PubMed ID: 23219433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
